Molecular Tumor Board: Integrating Biomarker Analyses into Clinical Decision-Making Regarding the Use of Immune Checkpoint Inhibitors in Cancer Treatment — April 3, 2017, Washington, DC | Research To Practice

Molecular Tumor Board: Integrating Biomarker Analyses into Clinical Decision-Making Regarding the Use of Immune Checkpoint Inhibitors in Cancer Treatment — April 3, 2017, Washington, DC

April 3, 2017, Washington, DC

Molecular Tumor Board: Integrating Biomarker Analyses into Clinical Decision-Making Regarding the Use of Immune Checkpoint Inhibitors in Cancer Treatment

Please note that slides are for review only and not to be repurposed or published.

MODULE 1:
Overview of Immune Checkpoint Inhibitors — Renal Cell Carcinoma and Urothelial Bladder Cancer (UBC) — Dr Drake

MODULE 2:
PD-L1 as a Predictive Biomarker in Non-Small Cell Lung Cancer (NSCLC) and Beyond — Dr Herbst

MODULE 3:
Checkpoint Inhibitors in Melanoma; Tumor-Infiltrating Lymphocytes (TILs) as Predictors of Response; Investigating the Immune State of the Tumor Microenvironment — Dr McDermott

MODULE 4:
Emerging Role of Immunotherapy in Gastrointestinal (GI) Cancers; Mutational and Neoantigen Burden as Predictors of Response — Dr Bendell

MODULE 5:
Checkpoint Inhibition in Hodgkin and Non-Hodgkin Lymphoma; Other Potential Biomarkers Predictive of Response — Dr Moskowitz